Here are the 424B prospectus supplements from BriaCell Therapeutics Corp. Warrant (BCTXZ) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow BCTXZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCTXZ filings page.
BriaCell Therapeutics Corp. is offering 1,449,300 common shares at an offering price of $3.25 per share pursuant to this prospectus supplement.
The placement agent for the offering is ThinkEquity LLC. Gross proceeds at the stated price are $4,710,225, with placement agent commissions of $353,267 (7.5%) and estimated net proceeds to the company of approximately $3.94 million. Closing of the offering is expected on or about June 2, 2026. The prospectus states common shares outstanding following the offering will be 8,699,787, and lists related equity instruments (warrants, options, RSUs, PSUs) with explicit counts and exercise/ conversion prices.